Colorectal Cancer
MDX-1105 for Advanced or Recurrent Cancer (UW08038)
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors
| Status | Conditions | Phase | Study ID |
| Recruiting | Renal Cell Carcinoma Non-small Cell Lung Cancer Malignant Melanoma Epithelial Ovarian Cancer |
Phase I |
UW08038 NCT00729664 |
Summary
The primary purpose of this study is to determine if MDX-1105 is safe and tolerated when administered every 14 days to subjects with selected advanced or recurrent solid tumors.
|
|
Eligibility Criteria (must meet the following to participate in this study)
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- ECOG PS 0 to 2
- Relapsed/refractory renal cell carcinoma,NSCLC,malignant melanoma, epithelial ovarian cancer
- Up to 5 previous systemic therapies
- Must have measurable disease
Exclusion Criteria:
- No history of severe hypersensitivity reactions to other monoclonal antibodies
- No prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody
- No active infection (viral, bacterial or fungal)
- No active autoimmune disease or a documented history of autoimmune
- No active or latent infection
Last Updated
May 25, 2012See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Please remember:
Please remember:
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.
Join Us On